# THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.

> **NCT00448279** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 58 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** trastuzumab
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT00448279
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2014-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00448279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00448279, "THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT00448279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*